Composition
Empagliflozin Tablets
Interested in this product?
Contact us for export pricing, bulk orders, and regulatory documentation.
Request QuoteProduct Overview
Empaberg contains Empagliflozin, an SGLT2 inhibitor with proven cardiovascular mortality reduction in type 2 diabetes patients with established CV disease.
Indication
Type 2 diabetes mellitus, reduction of cardiovascular death risk, and heart failure.
Packaging
10 x 10 Alu-Alu strip pack
Storage
Store below 25°C, protected from light.
Export Ready
Available for export with full regulatory documentation, COA, and dossier support for international registration.
Disclaimer: This product information is intended for healthcare professionals and authorized distributors only. It is not intended as medical advice. Please refer to the full prescribing information for complete details. Regulatory approvals may vary by country.